Creative Financial Designs Inc Savara Inc Transaction History

Creative Financial Designs Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 24, 2019	SELL	$6.27 - $10.92 $12,540 - $21,840	-2,000 Closed	0 $0
Q3 2018 Nov 02, 2018	SELL	$10.49 - $12.87 $19,983 - $24,517	-1,905 Reduced 48.78%	2,000 $22,000
Q2 2018 Jul 13, 2018	SELL	$8.55 - $13.76 $34,627 - $55,728	-4,050 Reduced 50.91%	3,905 $44,000
Q1 2018 May 02, 2018	BUY	$8.99 - $14.95 $44,743 - $74,406	4,977 Added 167.13%	7,955 $73,000
Q4 2017 May 02, 2018	BUY	$8.26 - $16.76 $24,598 - $49,911	2,978	2,978 $44,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Creative Financial Designs Inc , based on Form 13F filings with the SEC.

Stay updated on Creative Financial Designs Inc with notifications on news.